The Clinical Oncology Society of Australia (COSA) has recently published a position statement on Exercise in Cancer Care. COSA has called for “exercise to be embedded as part of standard practice in cancer care and to be viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment.” Read More >>https://goo.gl/r2R3MK
Congratulations to the #WFNMB and all parties involved in the success of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, Australia. We look forward to the 13th World Congress of the WFNMB to be hosted in Kyoto, Japan (2022).
National Operations Manager, Ms Julie Crouch, is presenting at the #WFNMB2018 conference within the ANZSNM Technologist SIG session
Theranostics Australia’s Ms Julie Crouch (National Operations Manager) will be presenting today at the #WFNMB2018 conference within the ANZSNM Technologist SIG session – “The Optimum Protocol for Ga-68 PSMA Within a Private Practice”. Best of luck to all the speakers involved.
Theranostics Australia is proud to be a Supporting Partner of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, April 20 – 24 2018 >> https://goo.gl/RaJBas
Theranostics Australia’s A/Prof Nat Lenzo will be presenting at Perth Urology Clinic’s GP Urology Masterclass on “theranostics” as a non-surgical cancer therapy. A/Prof Lenzo joins speakers from Perth Urological Clinic, Perth Radiology Clinic, Oncology West and GenesisCare. Topics include: female urology and OAB, urological stone disease, surgical andrology, male LUTS and BPH, urological oncology and non-surgical cancer therapy.
SCHOLARSHIP OPPORTUNITY: Telix Pharmaceuticals has partnered with Memorial Sloan Kettering Cancer Centre (MSKCC) to create a fully-funded place for an Australian undergraduate* to attend the Molecular Imaging Summer Program (MISP) in New York. (*subject to specific criteria). Read More/Apply here >> https://goo.gl/VX2BR4 **Applications can be sent directly to firstname.lastname@example.org up until the (extended) deadline of Feb 9th.**
Novartis AG (NVS) announced that Advanced Accelerator Applications (AAA), a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application or NDA for Lutathera, a treatment for somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), in adults. Read More>> https://goo.gl/AChzVF & https://goo.gl/kgZYSL
Christmas Closure: Theranostics Australia will be closed from the 23rd of December 2017 and will reopen on Monday 8th of January 2018.